Larixol
Larixol is an fMLP inhibitor and also inhibits Src kinase, ERK1/2, p38 and AKT phosphorylation signals in immune regulation. Larixol can interfere with the interaction between the βγ subunit of the fMLP receptor Gi protein and its downstream molecules, thereby inhibiting fMLP-induced respiratory burst. Larixol inhibits fMLP (0.1 μM) -induced superoxide anion production (IC50: 1.98 μM), cathepsin G release (IC50: 2.76 μM), and chemotaxis. Larixol improves neutrophil hyperactivation and reduces inflammation or tissue damage. A series of Larixol derivatives were found to have inhibitory effects on FSGS-related TRPC6 functional mutants[1][2].
Product Specifications
CAS Number
1438-66-0
Product Name Alternative
(+) -Larixol
UNSPSC
12352211
Hazard Statement
H315, H319, H335
Target
Akt; ERK; Src
Type
Natural Products
Related Pathways
MAPK/ERK Pathway; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/larixol.html
Purity
95.52
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
C[C@]12[C@@](C(C)(CCC2)C)([H])[C@H](CC([C@@H]1CC[C@](C)(O)C=C)=C)O
Molecular Formula
C20H34O2
Molecular Weight
306.48
Precautions
H315, H319, H335
References & Citations
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, sealed storage, away from moisture)
Scientific Category
Natural Products
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
CD56 / NCAM1 / NKH1 (Neuronal Cell Marker) (NCAM1/2217R), CF647 conjugate, 0.1mg/mL
